Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 8, 2008 Brian Orelli	Another FDA Safety Warning (Yawn) The FDA warning results from numerous reports of fungal infections in patients taking TNF inhibitors.
The Motley Fool April 29, 2011 Brian Orelli	Nice Efficacy, Pfizer, But... Safety data is most important at this point. Nothing can stop Pfizer's oral rheumatoid arthritis treatment tofacitinib.
The Motley Fool June 16, 2008 Brian Orelli	More Cancer Issues for Johnson & Johnson Potential cancer-causing side effects of Johnson & Johnson's drugs are like a tumor that continues to grow on the company.
The Motley Fool April 24, 2009 Brian Orelli	The Economy Strikes Again Amgen isn't recession-proof either.
The Motley Fool April 13, 2011 Brian Orelli	Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients.
The Motley Fool January 15, 2010 Brian Orelli	Oops, Sorry About That, Pfizer The FDA says there's no problem with Spiriva after all.
The Motley Fool April 27, 2009 Brian Orelli	Johnson & Johnson's Simponi Sticks to the Wall Johnson & Johnson gets its second-generation TNF-alpha inhibitor past the FDA.
The Motley Fool June 26, 2009 Brian Orelli	The $16 Billion Market That Could Make You Rich A large market just waiting to be taken over.
The Motley Fool March 4, 2011 Brian Orelli	Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors.
The Motley Fool October 8, 2010 Brian Orelli	Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size.
The Motley Fool February 27, 2008 Brian Orelli	Everyone's Picking on Anemia Drugs A new study in The Journal of the American Medical Association is adding fuel to the fire about Amgen's and Johnson & Johnson's anemia drugs. Should investors worry?
The Motley Fool October 19, 2010 Brian Orelli	When the Status Quo Is a Big Win The lack of an FDA rejection will do just fine. Amgen and Johnson & Johnson seemed to get through the FDA advisory panel process without much problem yesterday.
The Motley Fool June 9, 2008 Brian Orelli	Treading on a Johnson & Johnson Product Johnson & Johnson's Regranex, a drug for foot ulcers, gets a warning label.
The Motley Fool June 22, 2011 Brian Orelli	In-Licensing to the Rescue Abbott's latest deal could help shore things up.
The Motley Fool May 11, 2011 Brian Orelli	Abbott's Lucky Number Seven might be Abbott Labs' Humira's lucky number. The anti-inflammatory is up for approval in its seventh indication and the data looks pretty good.
The Motley Fool June 3, 2009 Brian Orelli	No More Triple-Digit Returns? If FDA decisions could be predicted easily, investors might not get to enjoy triple-digit returns, so perhaps we shouldn't be too upset about the tight-lipped nature of the FDA.
The Motley Fool April 13, 2009 Brian Orelli	Will These Drugs Get Past the FDA? Hopefully April won't bring showers of tears to these drugmakers: Eli Lilly... AstraZeneca... Bristol-Myers Squibb... Novo Nordisk... Johnson & Johnson...
Chemistry World September 24, 2010 Andrew Turley	End of the road for Avandia? The European Medicines Agency has decided the troubled diabetes drug should be pulled from the market while the US Food and Drug Administration has said it will 'significantly restrict' its use.
The Motley Fool November 17, 2008 Brian Orelli	Beauty Can Be a Beast Pinched pocketbooks are likely to hurt cosmetic-pharmaceutical companies more than any FDA warning.
The Motley Fool September 28, 2009 Brian Orelli	J&J's Knockout Drug J&J's Psoriasis drug Stelara beat Amgen's and Wyeth's Enbrel in a head-to-head competition, and considering the efficacy data, it shouldn't have much problems competing against the other psoriasis drugs.
The Motley Fool December 11, 2009 Brian Orelli	Roche and Biogen's Blockbuster Making Good Progress Roche and Biogen move their potential blockbuster through the clinical trial maze.
The Motley Fool August 28, 2008 Brian Orelli	Me-Too Drugs: Are They Worth It? These drugs have less risk, but also usually bring less of a reward to the companies that make them.
The Motley Fool July 14, 2011 Brian Orelli	Good Data, but Lots of Competition Regeneron's sarilumab passes a phase 2b trial.
The Motley Fool January 8, 2008 Brian Orelli	A Painful Reminder From the FDA The agency issues a reminder that osteoporosis drugs can cause severe pain.
The Motley Fool October 22, 2009 Brian Orelli	Good Luck in 2010, Amgen Just when it looked like Amgen was turning things around the Food and Drug Administration threw a wrench in the biotech's plans for its osteoporosis drug Prolia.
The Motley Fool June 18, 2010 Brian Orelli	Double the Approvals! Double the Fun! These twins will take it. sanofi-aventis and Novartis both received FDA approvals for their cancer drugs yesterday.
Chemistry World February 4, 2009 Matt Wilkinson	GSK targets autoimmune biologics GSK recently signed seven drug development deals that could see the company release a suite of drugs to treat inflammatory diseases ranging from rheumatoid arthritis to lupus.
The Motley Fool November 4, 2008 Brian Orelli	Does the Supreme Court Control Your Investment? The Supreme Court is about to make a decision that could affect drug company investors.
The Motley Fool March 4, 2010 Brian Orelli	Best in Class ... For Now Sanofi's new prostate cancer drug is better than nothing.
The Motley Fool August 25, 2009 Brian Orelli	How to Keep From Losing Your Shirt More side effects for weight-loss drugs -- maybe.
The Motley Fool November 27, 2009 Brian Orelli	A Mostly Meaningless FDA Approval After an accelerated approval, the positive effects of a full approval are minimal for Johnson & Johnson's drug, Intelence.
The Motley Fool May 14, 2007 Mike Havrilla	A Weaker Amgen Amgen's stock is trading lower after an FDA panel balked at two anemia drugs.
The Motley Fool April 23, 2008 Brian Orelli	Wyeth Recovers From Its Heartburn Wyeth deals with generic competition for one of its biggest drugs.
The Motley Fool July 24, 2009 Brian Orelli	Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday?
The Motley Fool November 29, 2011 Brian Orelli	Winners and Losers of Roche's Avastin Woes What the FDA giveth, the FDA can taketh away.
The Motley Fool July 9, 2009 Brian Orelli	Yes! It Can Handle the Pressure Rigel Pharmaceuticals' latest tests show that the side effects from its rheumatoid arthritis drug candidate R788 are manageable.
The Motley Fool May 27, 2010 Brian Orelli	This Rabid Agency Could Permanently Damage Your Portfolio The FDA has gotten a little out of control. The wonkiness of the FDA's actions makes it hard for investors to figure out what the agency will do.
The Motley Fool November 8, 2010 Brian Orelli	No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective.
The Motley Fool June 13, 2008 Brian Orelli	Some Insight Into Incyte's Data Incyte's rheumatoid arthritis drug looks promising, according to early numbers.
The Motley Fool October 4, 2007 Brian Orelli	Stopping the Inflammation Johnson & Johnson subsidiary Centocor announces positive phase 3 data for its psoriasis drug. Given the strong results from the trial, the company plans to file a marketing application for the drug by the end of the year.
The Motley Fool September 19, 2008 Brian Orelli	Skinning the Competition J&J's psoriasis drug candidate beats Amgen and Wyeth's Enbrel.
The Motley Fool September 28, 2010 Brian Orelli	Don't Get Stuck! Invest in Needle-Free Drugs Here's how to make some money off society's general disdain for needles through next-generation drugs.
The Motley Fool May 19, 2010 Brian Orelli	A Potential Blockbuster Bites the Dust. Should You Worry? Despite the gloomy headlines, investors shouldn't be upset that Roche and Biogen Idec have decided to end development of ocrelizumab for rheumatoid arthritis.
The Motley Fool July 8, 2008 Brian Lawler	Blockbuster Drugs Bound for Extinction? One of the biggest classes of prescription drugs, those for diabetes treatments, faces tougher FDA standards.
The Motley Fool June 12, 2008 Brian Orelli	Schering-Plough and J&J Score a Triple-Triple Schering-Plough and Johnson & Johnson present three phase 3 trials for a single drug, their anti-TNF medication golimumab.
The Motley Fool May 2, 2011 Brian Orelli	Prostate Cancer Drug Roars Ahead Johnson & Johnson's buy of Cougar paid off, but look in the rear view mirror.
The Motley Fool August 3, 2011 Brian Orelli	Ignore Pfizer's Financials for Now It's the pipeline that matters.
The Motley Fool June 23, 2010 Brian Orelli	Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise.
The Motley Fool July 15, 2010 Brian Orelli	The Blockbuster Drug Survives Another Body Blow Avandia is still standing.
BusinessWeek April 23, 2007 Alex Halperin	Vioxx Casts A Long, Long Shadow More than two years after Merck & Co. pulled its Vioxx painkiller from shelves over heart attack and stroke risks, the Food & Drug Administration is still skittish about the safety of drugs currently on the market and those coming up for review.